Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit Therapeutics’ ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug’s regulatory future unclear after mixed EGFR+ NSCLC results.

Read the full article here

Related Articles